Movement Alert|Summit Therapeutics PLC Falls 31.55% in Pre-Market Trading, FDA Rejects Lung Cancer Drug Application

Market Focus11-16 17:06

On November 16, Summit Therapeutics PLC fell 31.55% in Pre-Market Trading, trading at $10.6 per share, with turnover of $518,200.

The move followed disclosure that the FDA issued a complete response letter for the biologics license application for ivonescimab in previously treated advanced lung cancer, meaning the current filing was not approved.

According to the company update, the FDA said the application lacked statistically significant overall survival improvement data. While the Phase 3 HARMONi study showed progression-free survival improvement and an acceptable safety profile, the regulatory setback directly hit sentiment. Recent company disclosures had already highlighted a net loss of $208.4 million in the third quarter, R&D expense of $169.1 million, cash and investments of $629.8 million at the end of September, and shareholder approval to raise authorized common shares to 2 billion, reinforcing investor sensitivity to funding needs and potential dilution.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment